文献速递MDS 与骨髓增殖性肿瘤白血病

口服地西他滨/西达尿苷在慢性粒-单核细胞白血病亚群中的疗效与安全性:来自2期和3期研究

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
PubMed 文献 · Br J Haematol · 2025-06-16

分析2期和3期试验中慢性粒-单核细胞白血病(CMML)患者接受口服地西他滨/西达尿苷的疗效与安全性,33例可评估患者总缓解率76%,完全缓解率21%,中位总生存35.7个月,安全性与既往地西他滨报告相似。

要点

  • 33例CMML患者中总缓解率76%,完全缓解率21%。
  • 基线红细胞输注依赖的11例中46%获得≥12周输血独立。
  • 中位总生存35.7个月,无转化生存28.3个月。

核心结论

  • 口服地西他滨/西达尿苷在CMML患者中显示疗效,中位生存接近3年。

研究设计与样本

  • 分析2期和3期前瞻性随机试验中CMML亚组患者,筛查34例,33例接受治疗。

主要发现

  • 总缓解率76%,完全缓解率21%(n=7)。
  • 基线红细胞输注依赖的11例中46%获得≥12周输血独立,且与生存相关。
  • 中位总生存35.7个月,中位无转化生存28.3个月。
  • 安全性特征与既往报告的地西他滨相似。

关键数值与推荐

  • 76%(n=25)为骨髓增生异常型CMML。
  • 77%(n=24/31有DNA可测序)按CMML特异性预后评分系统为中危-2或高危。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DNA methyltransferase inhibitors (DNMTis) are commonly used in treating chronic myelomonocytic leukaemia (CMML); however, data from prospective studies of DNMTis in CMML are limited. The present analysis evaluated the efficacy, safety and pharmacodynamics of the oral DNMTi decitabine/cedazuridine in the subset of patients with CMML from the phase 2 and 3 trials, which led to the approval of this agent for myelodysplastic syndromes and CMML in the United States and Canada. Potential prognostic factors also were analysed. In all, 34 patients with CMML were screened and 33 were treated. Most patients (76% [n = 25]) had myelodysplastic type-CMML and 77% (n = 24/31 with DNA available for sequencing) had intermediate-2 or high-risk disease noted by CMML-specific prognostic scoring systems. The overall response rate was 76%, with 21% (n = 7) of patients achieving a complete response. Nearly half of the 11 patients who were red blood cell-transfusion dependent at baseline (46%) attained transfusion independence for ≥12 weeks, which was associated with survival. Median overall and transformation-free survival were 35.7 and 28.3 months, respectively, and the safety profile was similar to that previously reported for decitabine. This analysis described the use of decitabine/cedazuridine in CMML from consecutive, prospective, randomised trials and illustrated a median survival of nearly 3 years.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Savona MR, Odenike O, Roboz GJ, et al. Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies. Br J Haematol. 2025. PMID: 40524338. doi:10.1111/bjh.20203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。